NanoViricides Advances Antiviral Platform, Completes NV-387 Manufacturing

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage biotechnology company, has announced two significant developments that highlight its progress in antiviral therapeutics. The company will present at NIBA's 152nd Investment Conference in Fort Lauderdale on March 12, where President and Executive Chairman Anil R. Diwan will detail advancements in their broad-spectrum antiviral platform. This presentation comes at a crucial time as the company reports that manufacturing of its NV-387 Oral Gummies drug product has been completed, positioning the therapy for patient dosing once clinical sites are prepared. These developments signal important momentum for NanoViricides as it advances toward a Phase II trial for monkeypox in the Democratic Republic of Congo, following a successful Phase I safety study in healthy volunteers that reported no adverse events.

The company's lead drug candidate, NV-387, represents a potentially groundbreaking approach to antiviral treatment. This broad-spectrum antiviral is being developed to treat multiple respiratory viral infections including RSV, COVID, Long COVID, and Influenza, while also showing effectiveness in animal models for Monkeypox (MPox), Smallpox, and Measles. The completion of manufacturing for the oral gummy formulation marks a practical step toward making this treatment more accessible and patient-friendly. Additionally, the company has another advanced drug candidate, NV-HHV-1, targeting all Herpesvirus infections including HSV-1 "cold sores," HSV-2 "genital ulcers," VZV Shingles, and Chickenpox. While the company notes it cannot project exact dates for filing Investigational New Drug applications due to dependence on external collaborators, the current focus remains on advancing NV-387 into Phase II human clinical trials.

This news release was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN that focuses on biotechnology and life sciences sectors. The platform provides comprehensive distribution services including wire solutions via InvestorWire, article syndication to over 5,000 outlets, enhanced press release features, and social media distribution to millions of followers. For investors seeking the latest updates on NNVC, the company maintains a newsroom at https://ibn.fm/NNVC, while the full press release can be accessed at https://ibn.fm/AILOV. These developments position NanoViricides as a company to watch in the antiviral space, particularly as global health concerns about emerging and re-emerging viral threats continue to grow.